Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
63.31
+0.55 (0.88%)
At close: May 16, 2025, 4:00 PM
62.44
-0.87 (-1.37%)
After-hours: May 16, 2025, 7:59 PM EDT
Incyte Employees
Incyte had 2,617 employees as of December 31, 2024. The number of employees increased by 93 or 3.68% compared to the previous year.
Employees
2,617
Change (1Y)
93
Growth (1Y)
3.68%
Revenue / Employee
$1,686,368
Profits / Employee
$8,128
Market Cap
12.25B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2,617 | 93 | 3.68% |
Dec 31, 2023 | 2,524 | 200 | 8.61% |
Dec 31, 2022 | 2,324 | 230 | 10.98% |
Dec 31, 2021 | 2,094 | 321 | 18.10% |
Dec 31, 2020 | 1,773 | 317 | 21.77% |
Dec 31, 2019 | 1,456 | 89 | 6.51% |
Dec 31, 2018 | 1,367 | 159 | 13.16% |
Dec 31, 2017 | 1,208 | 228 | 23.27% |
Dec 31, 2016 | 980 | 288 | 41.62% |
Dec 31, 2015 | 692 | 104 | 17.69% |
Dec 31, 2014 | 588 | 107 | 22.25% |
Dec 31, 2013 | 481 | 68 | 16.46% |
Dec 31, 2012 | 413 | 45 | 12.23% |
Dec 31, 2011 | 368 | 121 | 48.99% |
Dec 31, 2010 | 247 | 26 | 11.76% |
Dec 31, 2009 | 221 | 9 | 4.25% |
Dec 31, 2008 | 212 | 16 | 8.16% |
Dec 31, 2007 | 196 | 10 | 5.38% |
Dec 31, 2006 | 186 | 9 | 5.08% |
Dec 31, 2005 | 177 | -9 | -4.84% |
Dec 31, 2004 | 186 | -268 | -59.03% |
Dec 31, 2003 | 454 | -37 | -7.54% |
Dec 31, 2002 | 491 | -94 | -16.07% |
Dec 31, 2001 | 585 | -737 | -55.75% |
Dec 31, 2000 | 1,322 | 214 | 19.31% |
Dec 31, 1999 | 1,108 | 241 | 27.80% |
Dec 31, 1998 | 867 | 191 | 28.25% |
Dec 31, 1997 | 676 | 218 | 47.60% |
Dec 31, 1996 | 458 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
INCY News
- 3 days ago - Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States - Business Wire
- 6 days ago - 20 stocks of companies showing excellent earnings-season trends even as the economy cools - Market Watch
- 10 days ago - Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 17 days ago - Incyte to Present at Upcoming Investor Conference - Business Wire
- 19 days ago - Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - Incyte raises 2025 sales forecast for blood cancer drug after solid quarter - Reuters
- 19 days ago - Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs - Business Wire
- 23 days ago - Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025 - Business Wire